WHO grants EUL for Covovax
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
2022 is going to be the year of opportunities and innovations from the medical industry in India
Effectiveness of Covaxin against the Omicron variant is currently being studied
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Sputnik M is a new member of the Sputnik vaccines family
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
Subscribe To Our Newsletter & Stay Updated